Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (AUPH) Revenue
Annual & quarterly revenue history · segment & region breakdown
AUPH · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAurinia Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.30B, an increase of 20.38% year-over-year from $0.28B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.28B | +$0.05B | +20.38% |
| 2024-12-31 | $0.24B | +$0.06B | +33.97% |
| 2023-12-31 | $0.18B | +$0.04B | +30.95% |
| 2022-12-31 | $0.13B | +$0.09B | +193.89% |
| 2021-12-31 | $0.05B | -$0.00B | -9.00% |
| 2020-12-31 | $0.05B | +$0.05B | +15660.38% |
| 2019-12-31 | $0.00B | -$0.00B | -31.32% |
| 2018-12-31 | $0.00B | +$0.00B | +10.24% |
| 2017-12-31 | $0.00B | +$0.00B | +142.77% |
| 2016-12-31 | $0.00B | -$0.00B | -26.38% |
Compare revenue vs peers
BiotechnologyCompare AUPH revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Aurinia Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Aurinia Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Aurinia Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AUPH revenue · 4 questionsAUPH's trailing twelve-month (TTM) revenue is $0.30B. That is an increase of 20.38% year-over-year from $0.28B in FY2025.
▸ Source: FMP · Aurinia Pharmaceuticals Inc. SEC filings · GAAP · Aurinia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026